The same group has also demonstrated delivery of the MSN encapsulating the anti-cancer drug, sunitinib in a significantly higher amount to the U87MG tumor by targeting VEGFR exploiting VEGF121 ligand in comparison with the non-targeted delivery [119]. The gene discussed is KDR; the disease is cancer.